XOMA Royalty (XOMA) Other Accumulated Expenses (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Other Accumulated Expenses came in at $747000.0 in Q1 2026, up 474.62% year-on-year from $130000.0 in Q1 2025, and up 598.13% quarter-over-quarter from $107000.0 in Q4 2025.
XOMA Royalty (XOMA) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Other Accumulated Expenses across 16 years of filings, most recently posting $747000.0 for Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $747000.0, up 474.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $747000.0 (up 474.62% YoY), and the FY2025 annual result was $107000.0, down 29.14% from the prior year.
- Other Accumulated Expenses came in at $747000.0 for Q1 2026 at XOMA Royalty, up from $107000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $747000.0 in Q1 2026 to a low of $20000.0 in Q2 2022.
- The 5-year median for Other Accumulated Expenses is $100000.0 (2023), against an average of $210294.1.
- Across the five-year window, Other Accumulated Expenses jumped 2315.0% in 2024 and dropped 29.14% in 2025, its largest moves.
- XOMA Royalty's Other Accumulated Expenses stood at $40000.0 in 2022, then jumped by 125.0% to $90000.0 in 2023, then soared by 67.78% to $151000.0 in 2024, then dropped by 29.14% to $107000.0 in 2025, then soared by 598.13% to $747000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $747000.0 (Q1 2026), $107000.0 (Q4 2025), and $456000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 747,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 456,000.00 |
| Jun 30, 2025 | 576,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 483,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 90,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Sep 30, 2022 | 30,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 84,000.00 |